• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IFF Reports Fourth Quarter and Full Year 2025 Results

    2/11/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials
    Get the next $IFF alert in real time by email

    Delivered solid top and bottom-line performance & advanced strategic priorities in 2025

    Launched sale process for the Food Ingredients segment

    Continuing to drive financial performance in 2026

    International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2025.

    Full year 2025 Consolidated Summary:

    Reported

     

    Adjusted

    (GAAP)

    (Non-GAAP)1

    Sales

     

    Loss Before Taxes

     

    EPS

     

    Operating EBITDA

     

    Operating EBITDA Margin

     

    EPS ex Amortization

    $10.9 B

     

    $(412) M

     

    $(1.46)

     

    $2.1 B

     

    19.2%

     

    $4.20

    Management Commentary

    "IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment," said Erik Fyrwald, CEO of IFF. "It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth."

    "We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improved our financial flexibility, allowing us to direct resources to our highest-value businesses."

    "Looking ahead to 2026, we are continuing to serve our customers with leading innovation to grow profitably with them and deliver financial performance across the company. While macroeconomic uncertainty persists, we are encouraged by the strength of our pipeline and the benefits of our reinvestment actions. We enter the year confident in our ability to deliver on our priorities and create long-term value for our shareholders."

    Full year 2025 Consolidated Financial Results

    • Reported net sales for the full year were $10.89 billion, a decrease of (5)% compared to the prior year. On a comparable basis2, currency neutral sales1 increased 2%, against a strong 6% year ago comparable, with mid-single digit growth in Taste and low-single digit performances in Health & Biosciences and Scent.
    • Loss before taxes on a reported basis for the full year was $412 million. Adjusted operating EBITDA1 for the full year was $2.086 billion. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7%, led by volume growth, productivity gains and favorable net pricing.
    • Reported earnings (loss) per share (EPS) for the full year was $(1.46). Adjusted EPS excluding amortization1 was $4.20 per diluted share.
    • Cash flow from operations for the full year was $850 million, and free cash flow1 defined as cash flow from operations less capital expenditures totaled $256 million. Total debt to trailing twelve months net income at the end of the fourth quarter was (16.2)x. Net debt to credit-adjusted EBITDA1 at the end of the full year was 2.6x.

    Full year 2025 Segment Summary: Growth vs. Prior Year

     

    Reported

    (GAAP)

     

    Comparable

    Currency

    Neutral

    (Non-GAAP)1 2

     

    Adjusted

    (Non-GAAP)1

     

    Comparable

    Currency

    Neutral

    Adjusted

    (Non-GAAP)1 2

     

    Sales

     

    Sales

     

    Operating EBITDA

     

    Operating EBITDA

    Taste

    2%

     

    4%

     

    4%

     

    10%

    Health & Biosciences

    4%

     

    3%

     

    3%

     

    7%

    Scent

    2%

     

    3%

     

    (6)%

     

    2%

    Food Ingredients

    (3)%

     

    (3)%

     

    4%

     

    10%

    Pharma Solutions

    (65)%

     

    12%

     

    (65)%

     

    16%

    Consolidated

    (5)%

     

    2%

     

    (5)%

     

    7%

    Taste Segment

    • On a reported basis, sales were $2.48 billion. On a comparable basis2, currency neutral sales1 increased 4% with broad-based growth in all regions.
    • Taste adjusted operating EBITDA1 was $478 million and adjusted operating EBITDA margin1 was 19.3% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 10% led by favorable net pricing, volume growth and productivity gains.

    Health & Biosciences Segment

    • On a reported basis, sales were $2.28 billion. On a comparable basis2, currency neutral sales1 increased 3% driven by growth in nearly all businesses led by a high-single digit increase in Food Biosciences and mid-single digit growth in Home & Personal Care and Animal Nutrition.
    • Health & Biosciences adjusted operating EBITDA1 was $594 million and adjusted operating EBITDA margin1 was 26.0% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 7% led primarily by volume growth and productivity gains.

    Scent Segment

    • On a reported basis, sales were $2.48 billion. On a comparable basis2, currency neutral sales1 improved 3% led by double-digit growth in Fine Fragrance and a low-single digit performance in Consumer Fragrance.
    • Scent adjusted operating EBITDA1 was $515 million and adjusted operating EBITDA margin1 was 20.8% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 2% led primarily by volume growth and productivity gains offset partially by reinvestment and unfavorable net pricing.

    Food Ingredients Segment

    • On a reported basis, sales were $3.28 billion. On a comparable basis2, currency neutral sales1 decreased (3)% as double-digit growth in Inclusions was offset primarily by softness in Protein Solutions as well as the proactive exit of low margin business over the course of 2025.
    • Food Ingredients adjusted operating EBITDA1 was $423 million and adjusted operating EBITDA margin1 was 12.9% for the full year. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 10% driven primarily by productivity gains and margin improvement initiatives.

    Fourth Quarter 2025 Consolidated Summary:

    Reported

    (GAAP)

     

    Adjusted

    (Non-GAAP)1

    Sales

     

    Income Before Taxes

     

    EPS

     

    Operating EBITDA

     

    Operating EBITDA Margin

     

    EPS ex Amortization

    $2.6 B

     

    $22 M

     

    $0.07

     

    $437 M

     

    16.9%

     

    $0.80

    Fourth Quarter 2025 Consolidated Financial Results

    • Reported net sales for the fourth quarter were $2.59 billion, a decrease of (7)% compared to the prior year period. On a comparable basis2, currency neutral sales1 increased 1% versus the prior year period, against a strong 6% year ago comparable, led by mid-single digit growth in Health & Biosciences and Scent and a low-single digit performance in Taste.
    • Income before taxes on a reported basis for the fourth quarter was $22 million. Adjusted operating EBITDA1 for the fourth quarter was $437 million. On a comparable basis2, currency neutral adjusted operating EBITDA1 increased 7% led primarily by productivity gains.
    • Reported earnings per share (EPS) for the fourth quarter was $0.07. Adjusted EPS excluding amortization1 was $0.80 per diluted share.

    Fourth Quarter 2025 Segment Summary: Growth vs. Prior Year

     

    Reported

    (GAAP)

     

    Comparable

    Currency Neutral

    Adjusted

    (Non-GAAP)1 2

     

    Adjusted

    (Non-GAAP)1

     

    Comparable

    Currency Neutral

    Adjusted

    (Non-GAAP)1 2

     

    Sales

     

    Sales

     

    Operating EBITDA

     

    Operating EBITDA

    Taste

    2%

     

    2%

     

    8%

     

    17%

    Health & Biosciences

    7%

     

    5%

     

    14%

     

    20%

    Scent

    6%

     

    4%

     

    0%

     

    1%

    Food Ingredients

    (2)%

     

    (4)%

     

    (18)%

     

    (11)%

    Consolidated

    (7)%

     

    1%

     

    (7)%

     

    7%

    Taste Segment

    • On a reported basis, sales were $588 million. On a comparable basis2, currency neutral sales1 increased 2%, with broad based growth in all regions led by a strong performance in North America.
    • Taste adjusted operating EBITDA1 was $94 million and adjusted operating EBITDA margin1 was 16% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 17% led primarily by favorable net pricing and cost discipline.

    Health & Biosciences Segment

    • On a reported basis, sales were $589 million. On a comparable basis2, currency neutral sales1 increased 5% as double-digit performances in Food Biosciences and Animal Nutrition and high-single digit growth in Home & Personal Care was partially offset by softness in Health, specifically in North America.
    • Health & Biosciences adjusted operating EBITDA1 was $155 million and adjusted operating EBITDA margin1 was 26.3% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 20% led by volume growth and productivity gains.

    Scent Segment

    • On a reported basis, sales were $610 million. On a comparable basis2, currency neutral sales1 improved 4% driven by double digit growth in Fine Fragrance and a mid-single digit performance in Consumer Fragrance.
    • Scent adjusted operating EBITDA1 was $106 million and adjusted operating EBITDA margin1 was 17.4% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 grew 1% as volume growth and productivity gains were partially offset by unfavorable net pricing.

    Food Ingredients Segment

    • On a reported basis, sales were $802 million. On a comparable basis2, currency neutral sales1 decreased (4)% as growth in Systems and Inclusions was offset primarily by softness in Protein Solutions and Emulsifiers & Sweeteners.
    • Food Ingredients adjusted operating EBITDA1 was $82 million and adjusted operating EBITDA margin1 was 10.2% in the fourth quarter. On a comparable basis2, currency neutral adjusted operating EBITDA1 declined (11)% as productivity gains were more than offset by lower volumes and unfavorable net price.

    2026 Financial Guidance

    Full year 2026 sales are expected to be in the range of $10.5 billion to $10.8 billion and full year 2026 adjusted operating EBITDA to be in the range of $2.05 billion to $2.15 billion. Full year guidance includes three months of our Soy Crush, Concentrates, and Lecithin business results with the divestiture assumed to close on March 31, 2026.

    The Company expects comparable currency neutral sales growth to be between 1% to 4%. Comparable currency neutral adjusted operating EBITDA is expected to grow at a faster rate than sales, growing 3% to 8% year-over-year.

    Based on recent market foreign exchange rates, the Company expects that foreign exchange will have an approximately 1% positive impact to sales growth and have no impact on adjusted operating EBITDA growth in 2026. The Company also expects that divestitures will have an approximately 5% adverse impact to both sales and adjusted operating EBITDA growth in 2026.

    A copy of the Company's Annual Report on Form 10-K will be available on its website at www.iff.com or at www.sec.gov by March 2, 2026.

    Audio Webcast

    A live webcast to discuss the Company's fourth quarter and full year 2025 financial results and outlook for 2026 will be held on February 12, 2026, at 9:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company's IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company's website approximately one hour after the event and will remain available on IFF's website for one year.

    Cautionary Statement Under The Private Securities Litigation Reform Act of 1995

    This press release includes statements that are not historical facts and are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the ongoing sale process for our Food Ingredients division), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management's present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially.

    Certain of such forward-looking information may be identified by such terms as "expect", "anticipate", "believe", "intend", "outlook", "may", "estimate", "should", "predict", "plan", "project", "could", and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes.

    Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in our end markets; (2) execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12); our indebtedness, credit rating liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations.

    The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under "Risk Factors" in our most recent Annual Report on Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference.

    We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.

    Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release.

    Use of Non-GAAP Financial Measures

    We provide in this press release non-GAAP financial measures, including: (i) comparable, currency neutral sales; (ii) adjusted operating EBITDA and comparable, currency neutral adjusted operating EBITDA; (iii) adjusted operating EBITDA margin; (iv) adjusted EPS ex amortization; (v) free cash flow; (vi) net debt to credit adjusted EBITDA; [and] (vii) adjusted selling and administrative expenses; and adjusted gross profit.

    Our non-GAAP financial measures are defined below.

    Comparable results for the fourth quarter and full year exclude the impact of divestitures.

    Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of subsidiary or segment performance. We also use currency neutral numbers when analyzing our performance against our competitors.

    Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization expense, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as, restructuring and other charges, impairment of goodwill, gains (losses) on business disposals, loss on assets classified as held for sale, divestiture and integration related costs, strategic initiative costs, regulatory costs and other items.

    Adjusted EPS ex Amortization excludes the impact of non-operational items including, restructuring and other charges, impairment of goodwill, divestitures and integration related costs, losses (gains) on business disposals, loss on assets classified as held for sale, pension settlement losses (gains), strategic initiative costs, regulatory costs, redemption value adjustment to EPS and other items that are not a part of recurring operations.

    Free Cash Flow is operating cash flow (i.e. cash flow from operations) less capital expenditures.

    Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items.

    Adjusted selling and administrative expenses exclude divestiture and integration related costs, strategic initiative costs, regulatory costs, entity realignment costs and other costs.

    Adjusted gross profit excludes divestiture and integration related costs.

    These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company's results under GAAP and may not be comparable to other companies' calculation of such metrics.

    We have also presented a non-GAAP measure, adjusted operating EBITDA, in the Financial Guidance provided above. Adjusted operating EBITDA is defined in the previous section of this release and we believe this measure is useful in understanding the Financial Guidance for the same reasons mentioned in that section. The comparable GAAP metric would be Net income (loss), which we do not provide guidance on. Reconciliations from such estimated GAAP metric to the presented non-GAAP metric would also require unreasonable effort because such reconciliations would depend upon events which are uncertain in timing or amounts, and activities which are not completely controlled by us. This includes, by way of illustration, possible transactions and related costs and amounts, known and unknown matters involving regulatory and other bodies and future events involving third parties.

    Welcome to IFF

    At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

    _______________________

    1 Schedules at the end of this release contain reconciliations of reported GAAP to Non-GAAP metrics. See Use of Non-GAAP Financial Measures for explanations of our Non-GAAP metrics.

    2 Comparable results for the fourth quarter and full year 2025 exclude the impact of divestitures.

     

    International Flavors & Fragrances Inc.

    Consolidated Statements of Income (Loss)

    (Amounts in millions except per share data)

    (Unaudited)

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2025

     

     

     

    2024

     

     

    % Change

     

     

    2025

     

     

     

    2024

     

     

    % Change

    Net sales

    $

    2,589

     

     

    $

    2,771

     

     

    (7

    )%

     

    $

    10,890

     

     

    $

    11,484

     

     

    (5

    )%

    Cost of sales

     

    1,699

     

     

     

    1,791

     

     

    (5

    )%

     

     

    6,952

     

     

     

    7,360

     

     

    (6

    )%

    Gross profit

     

    890

     

     

     

    980

     

     

    (9

    )%

     

     

    3,938

     

     

     

    4,124

     

     

    (5

    )%

    Research and development expenses

     

    174

     

     

     

    170

     

     

    2

    %

     

     

    694

     

     

     

    671

     

     

    3

    %

    Selling and administrative expenses

     

    469

     

     

     

    517

     

     

    (9

    )%

     

     

    1,834

     

     

     

    1,995

     

     

    (8

    )%

    Restructuring and other charges

     

    16

     

     

     

    23

     

     

    (30

    )%

     

     

    70

     

     

     

    29

     

     

    141

    %

    Amortization of acquisition-related intangibles

     

    134

     

     

     

    143

     

     

    (6

    )%

     

     

    568

     

     

     

    610

     

     

    (7

    )%

    Impairment of goodwill

     

    —

     

     

     

    —

     

     

    NMF

     

     

    1,153

     

     

     

    64

     

     

    NMF

    Losses (Gains) on sale of assets

     

    —

     

     

     

    —

     

     

    NMF

     

     

    1

     

     

     

    (11

    )

     

    (109

    )%

    Operating profit (loss)

     

    97

     

     

     

    127

     

     

    (24

    )%

     

     

    (382

    )

     

     

    766

     

     

    (150

    )%

    Interest expense

     

    49

     

     

     

    69

     

     

    (29

    )%

     

     

    229

     

     

     

    305

     

     

    (25

    )%

    Gain on extinguishment of debt

     

    —

     

     

     

    —

     

     

    NMF

     

     

    (488

    )

     

     

    —

     

     

    NMF

    (Gains) losses on business disposals

     

    (2

    )

     

     

    2

     

     

    (200

    )%

     

     

    109

     

     

     

    (346

    )

     

    (132

    )%

    Loss on assets classified as held for sale

     

    7

     

     

     

    33

     

     

    NMF

     

     

    115

     

     

     

    317

     

     

    NMF

    Other expense, net

     

    21

     

     

     

    138

     

     

    (85

    )%

     

     

    65

     

     

     

    182

     

     

    (64

    )%

    Income (loss) before income taxes

     

    22

     

     

     

    (115

    )

     

    (119

    )%

     

     

    (412

    )

     

     

    308

     

     

    (234

    )%

    Provision for (benefit from) income taxes

     

    4

     

     

     

    (55

    )

     

    (107

    )%

     

     

    (40

    )

     

     

    41

     

     

    (198

    )%

    Net income (loss)

     

    18

     

     

     

    (60

    )

     

    (130

    )%

     

     

    (372

    )

     

     

    267

     

     

    (239

    )%

    Net income attributable to non-controlling interest

     

    —

     

     

     

    —

     

     

    NMF

     

     

    2

     

     

     

    4

     

     

    (50

    )%

    Net income (loss) attributable to IFF shareholders

    $

    18

     

     

    $

    (60

    )

     

    (130

    )%

     

    $

    (374

    )

     

    $

    263

     

     

    (242

    )%

     

     

     

     

     

     

     

     

     

     

     

     

    Net income (loss) per share - basic

    $

    0.07

     

     

    $

    (0.23

    )

     

     

     

    $

    (1.46

    )

     

    $

    1.04

     

     

     

    Net income (loss) per share - diluted

    $

    0.07

     

     

    $

    (0.23

    )

     

     

     

    $

    (1.46

    )

     

    $

    1.04

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Average number of shares outstanding - basic

     

    256

     

     

     

    256

     

     

     

     

     

    256

     

     

     

    256

     

     

     

    Average number of shares outstanding - diluted

     

    257

     

     

     

    256

     

     

     

     

     

    256

     

     

     

    256

     

     

     

    NMF Not meaningful

    International Flavors & Fragrances Inc.

    Condensed Consolidated Balance Sheets

    (Amounts in millions)

    (Unaudited)

     

     

    December 31,

     

    2025

     

    2024

    Cash, cash equivalents and restricted cash

    $

    590

     

    $

    469

    Receivables, net

     

    1,731

     

     

    1,624

    Inventories

     

    2,245

     

     

    2,133

    Assets held for sale

     

    151

     

     

    3,056

    Prepaid expenses and other current assets

     

    877

     

     

    686

    Total current assets

     

    5,594

     

     

    7,968

     

     

     

     

    Property, plant and equipment, net

     

    4,029

     

     

    3,739

    Goodwill and other intangibles, net

     

    14,312

     

     

    15,520

    Other assets

     

    1,602

     

     

    1,496

    Total assets

    $

    25,537

     

    $

    28,723

     

     

     

     

    Short-term borrowings

    $

    1,254

     

    $

    1,413

    Other current liabilities

     

    2,679

     

     

    2,939

    Total current liabilities

     

    3,933

     

     

    4,352

     

     

     

     

    Long-term debt

     

    4,740

     

     

    7,564

    Non-current liabilities

     

    2,684

     

     

    2,938

     

     

     

     

    Shareholders' equity

     

    14,180

     

     

    13,869

    Total liabilities and shareholders' equity

    $

    25,537

     

    $

    28,723

    International Flavors & Fragrances Inc.

    Consolidated Statements of Cash Flows

    (Amounts in millions)

    (Unaudited)

     

     

    Year Ended December 31,

     

     

    2025

     

     

     

    2024

     

    Cash flows from operating activities:

     

     

     

    Net (loss) income

    $

    (372

    )

     

    $

    267

     

    Adjustments to reconcile to net cash provided by operations:

     

     

     

    Depreciation and amortization

     

    962

     

     

     

    1,015

     

    Deferred income taxes

     

    (251

    )

     

     

    (323

    )

    Loss on assets classified as held for sale

     

    115

     

     

     

    317

     

    Gains on sale of assets

     

    1

     

     

     

    (11

    )

    Losses (Gains) on business disposals

     

    109

     

     

     

    (346

    )

    Stock-based compensation

     

    88

     

     

     

    77

     

    Gain on extinguishment of debt

     

    (488

    )

     

     

    —

     

    Pension contributions

     

    (29

    )

     

     

    (29

    )

    Pension-related (benefit) expense

     

    (11

    )

     

     

    125

     

    Impairment of goodwill

     

    1,153

     

     

     

    64

     

    Changes in assets and liabilities, net of acquisitions:

     

     

     

    Trade receivables

     

    (68

    )

     

     

    (217

    )

    Inventories

     

    (41

    )

     

     

    (34

    )

    Accounts payable

     

    (57

    )

     

     

    40

     

    Accruals for incentive compensation

     

    (106

    )

     

     

    190

     

    Other assets/liabilities, net

     

    (155

    )

     

     

    (65

    )

    Net cash provided by operating activities

     

    850

     

     

     

    1,070

     

    Cash flows from investing activities:

     

     

     

    Additions to property, plant and equipment

     

    (594

    )

     

     

    (463

    )

    Additions to intangible assets

     

    (2

    )

     

     

    (5

    )

    Proceeds from disposal of assets

     

    21

     

     

     

    21

     

    Net proceeds received from business disposals

     

    2,743

     

     

     

    875

     

    Cash received (paid) on foreign currency forward contracts

     

    105

     

     

     

    (102

    )

    Joint venture capital contributions

     

    (4

    )

     

     

    —

     

    Net cash provided by investing activities

     

    2,269

     

     

     

    326

     

    Cash flows from financing activities:

     

     

     

    Cash dividends paid to shareholders

     

    (409

    )

     

     

    (514

    )

    Net borrowings (repayments) of commercial paper (maturities less than three months)

     

    314

     

     

     

    —

     

    Principal payments of debt

     

    (2,913

    )

     

     

    (1,030

    )

    Deferred and contingent consideration paid

     

    —

     

     

     

    (36

    )

    Withholding tax paid on stock-based compensation

     

    (24

    )

     

     

    (16

    )

    Purchase of treasury stock

     

    (38

    )

     

     

    —

     

    Other, net

     

    (21

    )

     

     

    (10

    )

    Net cash used in financing activities

     

    (3,091

    )

     

     

    (1,606

    )

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

    91

     

     

     

    (54

    )

    Net change in cash, cash equivalents and restricted cash

     

    119

     

     

     

    (264

    )

    Cash, cash equivalents and restricted cash at beginning of year

     

    471

     

     

     

    735

     

    Cash, cash equivalents and restricted cash at end of year

    $

    590

     

     

    $

    471

     

    The following table reconciles cash, cash equivalents and restricted cash between the Company's balance sheets as of December 31, 2025 and 2024 to the amounts reported on the Company's statement of cash flows for the periods ended December 31, 2025 and 2024.

    AMOUNTS IN MILLIONS

    December 31, 2025

     

    December 31, 2024

     

    December 31, 2023

    Current assets

     

     

     

     

     

    Cash and cash equivalents

    $

    590

     

    $

    469

     

    $

    703

    Cash and cash equivalents included in Assets held for sale

     

    —

     

     

    2

     

     

    26

    Restricted cash

     

    —

     

     

    —

     

     

    6

    Cash, cash equivalents and restricted cash

    $

    590

     

    $

    471

     

    $

    735

    International Flavors & Fragrances Inc.

    Reportable Segment Performance

    (Amounts in millions)

    (Unaudited)

     

     

    Three Months Ended December 31, 2025

     

    Taste

     

    Food Ingredients

     

    H&B

     

    Scent

     

    Total

    Net sales

    $

    588

     

     

    $

    802

     

     

    $

    589

     

     

    $

    610

     

     

    $

    2,589

    Cost of sales

     

    (367

    )

     

     

    (638

    )

     

     

    (322

    )

     

     

    (370

    )

     

     

    Research & development expenses

     

    (44

    )

     

     

    (15

    )

     

     

    (55

    )

     

     

    (61

    )

     

     

    Selling & administrative expenses

     

    (101

    )

     

     

    (100

    )

     

     

    (89

    )

     

     

    (91

    )

     

     

    Depreciation expense add-back (a)

     

    18

     

     

     

    33

     

     

     

    32

     

     

     

    18

     

     

     

    Adjusted Operating EBITDA

    $

    94

     

     

    $

    82

     

     

    $

    155

     

     

    $

    106

     

     

    $

    437

    Reconciliation of Adjusted Operating EBITDA:

     

    Total Adjusted Operating EBITDA

    $

    437

     

    Depreciation & Amortization

     

    (237

    )

    Interest Expense

     

    (49

    )

    Other Expense, Net

     

    (21

    )

    Restructuring and Other Charges (b)

     

    (16

    )

    Gains (Losses) on Business Disposals (c)

     

    2

     

    Loss on Assets Classified as Held for Sale (d)

     

    (7

    )

    Divestiture and Integration Related Costs (e)

     

    (35

    )

    Strategic Initiatives Costs (f)

     

    (11

    )

    Regulatory Costs (g)

     

    (35

    )

    Entity Realignment Costs (h)

     

    (3

    )

    Other (k)

     

    (3

    )

    Income (Loss) Before Taxes

    $

    22

     

    Segment Adjusted Operating EBITDA Margin

     

    Taste

    16.0

    %

    Food Ingredients

    10.2

    %

    Health & Biosciences

    26.3

    %

    Scent

    17.4

    %

    Consolidated

    16.9

    %

     

    Three Months Ended December 31, 2024

     

    Taste

     

    Food Ingredients

     

    H&B

     

    Scent

     

    Pharma

     

    Total

    Net sales

    $

    576

     

     

    $

    819

     

     

    $

    550

     

     

    $

    578

     

     

    $

    248

     

     

    $

    2,771

    Cost of sales

     

    (360

    )

     

     

    (630

    )

     

     

    (298

    )

     

     

    (330

    )

     

     

    (173

    )

     

     

    Research & development expenses

     

    (43

    )

     

     

    (13

    )

     

     

    (50

    )

     

     

    (58

    )

     

     

    (6

    )

     

     

    Selling & administrative expenses

     

    (104

    )

     

     

    (108

    )

     

     

    (95

    )

     

     

    (101

    )

     

     

    (31

    )

     

     

    Depreciation expense add-back (a)

     

    18

     

     

     

    32

     

     

     

    29

     

     

     

    17

     

     

     

    4

     

     

     

    Adjusted Operating EBITDA

    $

    87

     

     

    $

    100

     

     

    $

    136

     

     

    $

    106

     

     

    $

    42

     

     

    $

    471

    Reconciliation of Adjusted Operating EBITDA:

     

    Total Adjusted Operating EBITDA

    $

    471

     

    Depreciation & Amortization

     

    (243

    )

    Interest Expense

     

    (69

    )

    Other Expense, Net

     

    (138

    )

    Restructuring and Other Charges (b)

     

    (23

    )

    Gains (Losses) on Business Disposals (c)

     

    (2

    )

    Loss on Assets Classified as Held for Sale (d)

     

    (33

    )

    Divestiture and Integration Related Costs (e)

     

    (56

    )

    Strategic Initiatives Costs (f)

     

    (11

    )

    Regulatory Costs (g)

     

    (9

    )

    Other (k)

     

    (2

    )

    Income (Loss) Before Taxes

    $

    (115

    )

    Segment Adjusted Operating EBITDA Margin

     

    Taste

    15.1

    %

    Food Ingredients

    12.2

    %

    Health & Biosciences

    24.7

    %

    Scent

    18.3

    %

    Pharma Solutions

    16.9

    %

    Consolidated

    17.0

    %

     

    Twelve Months Ended December 31, 2025

     

    Taste

     

    Food Ingredients

     

    H&B

     

    Scent

     

    Pharma

     

    Total

    Net sales

    $

    2,481

     

     

    $

    3,278

     

     

    $

    2,283

     

     

    $

    2,479

     

     

    $

    369

     

     

    $

    10,890

    Cost of sales

     

    (1,500

    )

     

     

    (2,531

    )

     

     

    (1,246

    )

     

     

    (1,424

    )

     

     

    (248

    )

     

     

    Research & development expenses

     

    (172

    )

     

     

    (54

    )

     

     

    (219

    )

     

     

    (241

    )

     

     

    (8

    )

     

     

    Selling & administrative expenses

     

    (396

    )

     

     

    (400

    )

     

     

    (348

    )

     

     

    (366

    )

     

     

    (42

    )

     

     

    Depreciation expense add-back (a)

     

    65

     

     

     

    130

     

     

     

    124

     

     

     

    67

     

     

     

    5

     

     

     

    Adjusted Operating EBITDA

    $

    478

     

     

    $

    423

     

     

    $

    594

     

     

    $

    515

     

     

    $

    76

     

     

    $

    2,086

    Reconciliation of Adjusted Operating EBITDA:

     

    Total Adjusted Operating EBITDA

    $

    2,086

     

    Depreciation & Amortization

     

    (962

    )

    Interest Expense

     

    (229

    )

    Other Expense, Net

     

    (65

    )

    Restructuring and Other Charges (b)

     

    (70

    )

    Impairment of Goodwill (i)

     

    (1,153

    )

    Gains (Losses) on Business Disposals (c)

     

    (109

    )

    Loss on Assets Classified as Held for Sale (d)

     

    (115

    )

    Gain on Extinguishment of Debt (j)

     

    488

     

    Divestiture and Integration Related Costs (e)

     

    (125

    )

    Strategic Initiatives Costs (f)

     

    (35

    )

    Regulatory Costs (g)

     

    (106

    )

    Entity Realignment Costs (h)

     

    (8

    )

    Other (k)

     

    (9

    )

    Income (Loss) Before Taxes

    $

    (412

    )

    Segment Adjusted Operating EBITDA Margin

     

    Taste

    19.3

    %

    Food Ingredients

    12.9

    %

    Health & Biosciences

    26.0

    %

    Scent

    20.8

    %

    Pharma Solutions

    20.6

    %

    Consolidated

    19.2

    %

     

    Twelve Months Ended December 31, 2024

     

    Taste

     

    Food Ingredients

     

    H&B

     

    Scent

     

    Pharma

     

    Total

    Net sales

    $

    2,428

     

     

    $

    3,365

     

     

    $

    2,203

     

     

    $

    2,439

     

     

    $

    1,049

     

     

    $

    11,484

    Cost of sales

     

    (1,470

    )

     

     

    (2,626

    )

     

     

    (1,183

    )

     

     

    (1,361

    )

     

     

    (719

    )

     

     

    Research & development expenses

     

    (160

    )

     

     

    (71

    )

     

     

    (190

    )

     

     

    (225

    )

     

     

    (25

    )

     

     

    Selling & administrative expenses

     

    (403

    )

     

     

    (391

    )

     

     

    (368

    )

     

     

    (376

    )

     

     

    (115

    )

     

     

    Depreciation expense add-back (a)

     

    65

     

     

     

    131

     

     

     

    115

     

     

     

    68

     

     

     

    25

     

     

     

    Adjusted Operating EBITDA

    $

    460

     

     

    $

    408

     

     

    $

    577

     

     

    $

    545

     

     

    $

    215

     

     

    $

    2,205

    Reconciliation of Adjusted Operating EBITDA:

     

    Total Adjusted Operating EBITDA

    $

    2,205

     

    Depreciation & Amortization

     

    (1,015

    )

    Interest Expense

     

    (305

    )

    Other Expense, Net

     

    (182

    )

    Restructuring and Other Charges (b)

     

    (29

    )

    Impairment of Goodwill (i)

     

    (64

    )

    Gains (Losses) on Business Disposals (c)

     

    346

     

    Loss on Assets Classified as Held for Sale (d)

     

    (317

    )

    Divestiture and Integration Related Costs (e)

     

    (228

    )

    Strategic Initiatives Costs (f)

     

    (33

    )

    Regulatory Costs (g)

     

    (73

    )

    Entity Realignment Costs (h)

     

    (6

    )

    Other (k)

     

    9

     

    Income (Loss) Before Taxes

    $

    308

     

    Segment Adjusted Operating EBITDA Margin

     

    Taste

    18.9

    %

    Food Ingredients

    12.1

    %

    Health & Biosciences

    26.2

    %

    Scent

    22.3

    %

    Pharma Solutions

    20.5

    %

    Consolidated

    19.2

    %

    (a)

    There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results.

    (b)

    For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.

    (c)

    For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and Rene Laurent business in France. For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the Flavors & Essences UK business.

    (d)

    For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.

    (e)

    For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

    (f)

    Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. For 2024, also includes strategic initiatives related to the Company's business unit re-organization efforts.

    (g)

    Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

    (h)

    Represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework.

    (i)

    For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. For 2024, represents the impairment of goodwill related to the Pharma Solutions disposal group.

    (j)

    For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers.

    (k)

    For 2025, primarily represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2025, also includes the impact of legislation changes in India related to the Wage Code. For 2024, primarily represents gains from sale of assets.

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    (Unaudited)

    The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

    Reconciliation of Gross Profit

     

    Fourth Quarter

    (DOLLARS IN MILLIONS)

    2025

     

    2024

    Reported (GAAP)

    $

    890

     

    $

    980

    Divestiture and Integration Related Costs (b)

     

    1

     

     

    —

    Adjusted (Non-GAAP)

    $

    891

     

    $

    980

    Reconciliation of Selling and Administrative Expenses

     

    Fourth Quarter

    (DOLLARS IN MILLIONS)

     

    2025

     

     

     

    2024

     

    Reported (GAAP)

    $

    469

     

     

    $

    517

     

    Divestiture and Integration Related Costs (b)

     

    (34

    )

     

     

    (56

    )

    Strategic Initiatives Costs (f)

     

    (11

    )

     

     

    (11

    )

    Regulatory Costs (g)

     

    (36

    )

     

     

    (9

    )

    Entity Realignment Costs (h)

     

    (3

    )

     

     

    (2

    )

    Other (i)

     

    (2

    )

     

     

    —

     

    Adjusted (Non-GAAP)

    $

    383

     

     

    $

    439

     

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    (Unaudited)

    The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

    Reconciliation of Net Income (Loss) and EPS

     

    Fourth Quarter

     

    2025

     

    2024

    (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)

    Income (loss) before taxes

     

    Provision from Income taxes (j)

     

    Net income (loss) attributable to IFF

     

    Diluted EPS

     

    (Loss) income before taxes

     

    Benefit from Income taxes (j)

     

    Net (loss) income attributable to IFF

     

    Diluted EPS

    Reported (GAAP)

    $

    22

     

     

    $

    4

     

     

    $

    18

     

     

    $

    0.07

     

     

    $

    (115

    )

     

    $

    (55

    )

     

    $

    (60

    )

     

    $

    (0.23

    )

    Restructuring and Other Charges (a)

     

    16

     

     

     

    4

     

     

     

    12

     

     

     

    0.05

     

     

     

    23

     

     

     

    6

     

     

     

    17

     

     

     

    0.07

     

    Divestiture and Integration Related Costs (b)

     

    35

     

     

     

    9

     

     

     

    26

     

     

     

    0.10

     

     

     

    56

     

     

     

    12

     

     

     

    44

     

     

     

    0.16

     

    (Gains) Losses on Business Disposals (c)

     

    (2

    )

     

     

    (4

    )

     

     

    2

     

     

     

    —

     

     

     

    2

     

     

     

    (1

    )

     

     

    3

     

     

     

    0.01

     

    Loss on Assets Classified as Held for Sale (d)

     

    7

     

     

     

    2

     

     

     

    5

     

     

     

    0.02

     

     

     

    33

     

     

     

    8

     

     

     

    25

     

     

     

    0.10

     

    Pension Settlement (Gains) Losses (e)

     

    (6

    )

     

     

    (1

    )

     

     

    (5

    )

     

     

    (0.02

    )

     

     

    129

     

     

     

    45

     

     

     

    84

     

     

     

    0.33

     

    Strategic Initiatives Costs (f)

     

    11

     

     

     

    3

     

     

     

    8

     

     

     

    0.04

     

     

     

    11

     

     

     

    3

     

     

     

    8

     

     

     

    0.03

     

    Regulatory Costs (g)

     

    35

     

     

     

    2

     

     

     

    33

     

     

     

    0.13

     

     

     

    9

     

     

     

    2

     

     

     

    7

     

     

     

    0.02

     

    Entity Realignment Costs (h)

     

    3

     

     

     

    1

     

     

     

    2

     

     

     

    0.01

     

     

     

    2

     

     

     

    1

     

     

     

    1

     

     

     

    0.03

     

    Other (i)

     

    3

     

     

     

    —

     

     

     

    3

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Adjusted (Non-GAAP)

    $

    124

     

     

    $

    20

     

     

    $

    104

     

     

    $

    0.40

     

     

    $

    150

     

     

    $

    21

     

     

    $

    129

     

     

    $

    0.52

     

    Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization

     

    Fourth Quarter

    (DOLLARS AND SHARE AMOUNTS IN MILLIONS)

    2025

     

    2024

    Numerator

     

     

     

    Adjusted (Non-GAAP) Net Income

    $

    104

     

    $

    129

    Amortization of Acquisition-related Intangible Assets

     

    134

     

     

    143

    Tax impact on Amortization of Acquisition-related Intangible Assets (j)

     

    32

     

     

    35

    Amortization of Acquisition-related Intangible Assets, net of tax (k)

     

    102

     

     

    108

    Adjusted (Non-GAAP) Net Income ex. Amortization

    $

    206

     

    $

    237

     

     

     

     

    Denominator

     

     

     

    Weighted average shares assuming dilution (diluted)

     

    257

     

     

    256

    Adjusted (Non-GAAP) EPS ex. Amortization

    $

    0.80

     

    $

    0.93

    (a)

    For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.

    (b)

    For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

     

    For the three months ended December 31, 2025 and December 31, 2024, business divestiture costs were approximately $35 million and $56 million, respectively.

    (c)

    For 2025, primarily represents the gain recognized related to the divestiture of the Rene Laurent business in France. For 2024, primarily represents the impact of adjustments to the gain recognized related to the divestiture of the Cosmetic Ingredients business.

    (d)

    For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group.

    (e)

    For 2024, represents a settlement loss that was recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. During 2025, a reduction of the previous settlement loss was recognized.

    (f)

    For 2025 and 2024, represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Service Centers, primarily consulting fees.

    (g)

    Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

    (h)

    For 2025 and 2024, represents costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees.

    (i)

    For 2025, primarily represents the impact of legislation changes in India related to the Wage Code.

    (j)

    The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

    (k)

    Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    (Unaudited)

    The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

    Reconciliation of Gross Profit

     

    Year Ended December 31,

    (DOLLARS IN MILLIONS)

    2025

     

    2024

    Reported (GAAP)

    $

    3,938

     

    $

    4,124

    Divestiture and Integration Related Costs (b)

     

    1

     

     

    1

    Adjusted (Non-GAAP)

    $

    3,939

     

    $

    4,125

    Reconciliation of Selling and Administrative Expenses

     

    Year Ended December 31,

    (DOLLARS IN MILLIONS)

     

    2025

     

     

     

    2024

     

    Reported (GAAP)

    $

    1,834

     

     

    $

    1,995

     

    Divestiture and Integration Related Costs (b)

     

    (123

    )

     

     

    (227

    )

    Strategic Initiatives Costs (g)

     

    (35

    )

     

     

    (33

    )

    Regulatory Costs (h)

     

    (106

    )

     

     

    (73

    )

    Entity Realignment Costs (j)

     

    (8

    )

     

     

    (6

    )

    Other (l)

     

    (8

    )

     

     

    (2

    )

    Adjusted (Non-GAAP)

    $

    1,554

     

     

    $

    1,654

     

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    (Unaudited)

    The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

    Reconciliation of Net (Loss) Income and EPS

     

    Year Ended December 31,

     

    2025

     

    2024

    (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS)

    (Loss) income before taxes

     

    Benefit for income taxes (m)

     

    Net (loss) income attributable to IFF (n)

     

    Diluted EPS

     

    Income (loss) before taxes

     

    Provision for income taxes (m)

     

    Net income (loss) attributable to IFF (n)

     

    Diluted EPS

    Reported (GAAP)

    $

    (412

    )

     

    $

    (40

    )

     

    $

    (374

    )

     

    $

    (1.46

    )

     

    $

    308

     

     

    $

    41

     

     

    $

    263

     

     

    $

    1.04

     

    Restructuring and Other Charges (a)

     

    70

     

     

     

    16

     

     

     

    54

     

     

     

    0.21

     

     

     

    29

     

     

     

    7

     

     

     

    22

     

     

     

    0.09

     

    Divestiture and Integration Related Costs (b)

     

    125

     

     

     

    46

     

     

     

    79

     

     

     

    0.31

     

     

     

    225

     

     

     

    50

     

     

     

    175

     

     

     

    0.68

     

    Impairment of Goodwill (c)

     

    1,153

     

     

     

    7

     

     

     

    1,146

     

     

     

    4.48

     

     

     

    64

     

     

     

    —

     

     

     

    64

     

     

     

    0.25

     

    Losses (Gains) on Business Disposals (d)

     

    109

     

     

     

    (153

    )

     

     

    262

     

     

     

    1.02

     

     

     

    (346

    )

     

     

    (24

    )

     

     

    (322

    )

     

     

    (1.26

    )

    Loss on Assets Classified as Held for Sale (e)

     

    115

     

     

     

    27

     

     

     

    88

     

     

     

    0.34

     

     

     

    317

     

     

     

    66

     

     

     

    251

     

     

     

    0.98

     

    Pension Settlement (Gains) Losses (f)

     

    (6

    )

     

     

    (1

    )

     

     

    (5

    )

     

     

    (0.02

    )

     

     

    129

     

     

     

    45

     

     

     

    84

     

     

     

    0.33

     

    Strategic Initiatives Costs (g)

     

    35

     

     

     

    8

     

     

     

    27

     

     

     

    0.11

     

     

     

    33

     

     

     

    8

     

     

     

    25

     

     

     

    0.10

     

    Regulatory Costs (h)

     

    106

     

     

     

    19

     

     

     

    87

     

     

     

    0.34

     

     

     

    73

     

     

     

    13

     

     

     

    60

     

     

     

    0.23

     

    Gain on Debt Extinguishment (i)

     

    (488

    )

     

     

    (116

    )

     

     

    (372

    )

     

     

    (1.45

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Entity Realignment Costs (j)

     

    8

     

     

     

    362

     

     

     

    (354

    )

     

     

    (1.38

    )

     

     

    6

     

     

     

    2

     

     

     

    4

     

     

     

    0.02

     

    U.S. Tax Reform (k)

     

    —

     

     

     

    1

     

     

     

    (1

    )

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Other (l)

     

    9

     

     

     

    1

     

     

     

    8

     

     

     

    0.02

     

     

     

    (9

    )

     

     

    (4

    )

     

     

    (5

    )

     

     

    (0.02

    )

    Adjusted (Non-GAAP)

    $

    824

     

     

    $

    177

     

     

    $

    645

     

     

    $

    2.52

     

     

    $

    829

     

     

    $

    204

     

     

    $

    621

     

     

    $

    2.44

     

    Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization

     

    Year Ended December 31,

    (DOLLARS AND SHARE AMOUNTS IN MILLIONS)

    2025

     

    2024

    Numerator

     

     

     

    Adjusted (Non-GAAP) Net Income

    $

    645

     

    $

    621

    Amortization of Acquisition-related Intangible Assets

     

    568

     

     

    610

    Tax impact on Amortization of Acquisition-related Intangible Assets (m)

     

    138

     

     

    150

    Amortization of Acquisition-related Intangible Assets, net of tax (o)

     

    430

     

     

    460

    Adjusted (Non-GAAP) Net Income ex. Amortization

    $

    1,075

     

    $

    1,081

     

     

     

     

    Denominator

     

     

     

    Weighted average shares assuming dilution (diluted)

     

    256

     

     

    256

    Adjusted (Non-GAAP) EPS ex. Amortization

    $

    4.20

     

    $

    4.22

    (a)

    For 2025, represents costs related to the IFF Productivity Program including severance, fixed asset write-downs and site closure expenses, net of the gain on sale of fixed assets previously written down. For 2024, represents initial costs in connection with the IFF Productivity Program, primarily related to fixed asset write-downs.

    (b)

    For 2025 and 2024, primarily represents costs related to the Company's completed and anticipated divestitures. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts.

     

    For the year-ended December 31, 2025, business divestiture costs were approximately $125 million. For the year-ended December 31, 2024, business divestiture and integration related costs were approximately $220 million and $5 million, respectively.

    (c)

    For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit. For 2024, represents the impairment of goodwill related to the Pharma Solutions disposal group.

    (d)

    For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business and Rene Laurent business in France. For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the Flavors & Essences UK business.

    (e)

    For 2025, represents the losses recognized on assets classified as held for sale of the Soy, Concentrates and Lecithin disposal group. For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.

    (f)

    For 2024, represents a settlement loss that was recognized as a result of the termination of the International Flavors & Fragrances Inc. Pension Plan. During 2025, a reduction of the previous settlement loss was recognized.

    (g)

    Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. For 2024, also includes strategic initiatives related to the Company's business unit re-organization efforts.

    (h)

    Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses.

    (i)

    For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of tender offers.

    (j)

    For 2025 and 2024, represents costs related to a phased restructuring initiative aimed at optimizing its legal entity framework. In 2025, a one-time tax benefit was achieved as part of this restructuring which is partially offset by the execution costs to implement.

    (k)

    Tax benefit related to the impacts of the One Big Beautiful Bill Act, effective for 2025.

    (l)

    For 2025, primarily represents the net impact of costs related to severance, including accelerated stock compensation expense, for certain executives who have separated from the Company. For 2025, also includes the impact of legislation changes in India related to the Wage Code. For 2024, primarily represents gains from sale of assets.

    (m)

    The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments.

    (n)

    For 2025, reported net loss is decreased by income attributable to non-controlling interest of $2 million and adjusted net loss is decreased by income attributable to non-controlling interest of $2 million. For 2024, reported net income is decreased by income attributable to non-controlling interest of $4 million and adjusted net income is decreased by income attributable to non-controlling interest of $4 million.

    (o)

    Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

    International Flavors & Fragrances Inc.

    Debt Covenants

    (Amounts in millions)

    (Unaudited)

    The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

    Reconciliation of Credit Adjusted EBITDA to Net Income

    (DOLLARS IN MILLIONS)

    Year Ended December 31, 2025

    Net income

    $

    (372

    )

    Interest expense

     

    229

     

    Income taxes

     

    (40

    )

    Depreciation and amortization

     

    962

     

    Specified items(1)

     

    1,018

     

    Non-cash items(2)

     

    303

     

    Credit Adjusted EBITDA

    $

    2,100

     

    _______________________

    (1)

    Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture and integration related costs, strategic initiatives costs, regulatory costs and other costs that are not related to recurring operations.

    (2)

    Non-cash items consisted of losses (gains) on sale of assets, losses (gains) on business disposals, losses on assets classified as held for sale, reduction of previous pension settlement losses, and stock-based compensation.

    Net Debt to Total Debt

    (DOLLARS IN MILLIONS)

    December 31, 2025

    Total debt(1)

    $

    6,026

    Adjustments:

     

    Cash and cash equivalents

     

    590

    Net debt

    $

    5,436

    _______________________

    (1)

    Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations.

    International Flavors & Fragrances Inc.

    Comparable Reportable Segment Performance

    (Amounts in millions)

    (Unaudited)

    The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net Sales

     

     

     

     

     

     

     

    Taste(1)

    $

    588

     

     

    $

    573

     

     

    $

    2,481

     

     

    $

    2,410

     

    Food Ingredients

     

    802

     

     

     

    819

     

     

     

    3,278

     

     

     

    3,365

     

    Health & Biosciences

     

    589

     

     

     

    550

     

     

     

    2,283

     

     

     

    2,203

     

    Scent(2)

     

    610

     

     

     

    578

     

     

     

    2,479

     

     

     

    2,412

     

    Pharma Solutions(3)

     

    —

     

     

     

    —

     

     

     

    369

     

     

     

    337

     

    Consolidated

    $

    2,589

     

     

    $

    2,520

     

     

    $

    10,890

     

     

    $

    10,727

     

    Segment Adjusted Operating EBITDA(5)

     

     

     

     

     

     

     

    Taste(1)

    $

    94

     

     

    $

    82

     

     

    $

    478

     

     

    $

    446

     

    Food Ingredients

     

    82

     

     

     

    97

     

     

     

    423

     

     

     

    399

     

    Health & Biosciences

     

    155

     

     

     

    132

     

     

     

    594

     

     

     

    568

     

    Scent(2)

     

    106

     

     

     

    105

     

     

     

    515

     

     

     

    526

     

    Pharma Solutions(3)

     

    —

     

     

     

    —

     

     

     

    76

     

     

     

    68

     

    Total

     

    437

     

     

     

    416

     

     

     

    2,086

     

     

     

    2,007

     

    Depreciation & Amortization

     

    (237

    )

     

     

    (243

    )

     

     

    (962

    )

     

     

    (1,015

    )

    Interest Expense

     

    (49

    )

     

     

    (69

    )

     

     

    (229

    )

     

     

    (305

    )

    Other Expense, Net

     

    (21

    )

     

     

    (138

    )

     

     

    (65

    )

     

     

    (182

    )

    Restructuring and Other Charges

     

    (16

    )

     

     

    (23

    )

     

     

    (70

    )

     

     

    (29

    )

    Impairment of Goodwill

     

    —

     

     

     

    —

     

     

     

    (1,153

    )

     

     

    (64

    )

    Gains (Losses) on Business Disposals

     

    2

     

     

     

    (2

    )

     

     

    (109

    )

     

     

    346

     

    Loss on Assets Classified as Held for Sale

     

    (7

    )

     

     

    (33

    )

     

     

    (115

    )

     

     

    (317

    )

    Gain on Extinguishment of Debt

     

    —

     

     

     

    —

     

     

     

    488

     

     

     

    —

     

    Divestiture and Integration Related Costs

     

    (35

    )

     

     

    (56

    )

     

     

    (125

    )

     

     

    (228

    )

    Strategic Initiatives Costs

     

    (11

    )

     

     

    (11

    )

     

     

    (35

    )

     

     

    (33

    )

    Regulatory Costs

     

    (35

    )

     

     

    (9

    )

     

     

    (106

    )

     

     

    (73

    )

    Entity Realignment Costs

     

    (3

    )

     

     

    —

     

     

     

    (8

    )

     

     

    (6

    )

    Other

     

    (3

    )

     

     

    (2

    )

     

     

    (9

    )

     

     

    9

     

    Impact of Business Divestitures(4)

     

    —

     

     

     

    55

     

     

     

    —

     

     

     

    198

     

    Income (Loss) Before Taxes

    $

    22

     

     

    $

    (115

    )

     

    $

    (412

    )

     

    $

    308

     

     

     

     

     

     

     

     

     

    Segment Adjusted Operating EBITDA Margin

     

     

     

     

     

     

     

    Taste

     

    16.0

    %

     

     

    14.3

    %

     

     

    19.3

    %

     

     

    18.5

    %

    Food Ingredients

     

    10.2

    %

     

     

    11.8

    %

     

     

    12.9

    %

     

     

    11.9

    %

    Health & Biosciences

     

    26.3

    %

     

     

    24.0

    %

     

     

    26.0

    %

     

     

    25.8

    %

    Scent

     

    17.4

    %

     

     

    18.2

    %

     

     

    20.8

    %

     

     

    21.8

    %

    Pharma Solutions

     

    —

    %

     

     

    —

    %

     

     

    20.6

    %

     

     

    20.2

    %

    Consolidated

     

    16.9

    %

     

     

    16.5

    %

     

     

    19.2

    %

     

     

    18.7

    %

    ______________________

    (1)

    Taste sales and segment adjusted operating EBITDA information for the three months and year-ended December 31, 2024 exclude the results of the Flavors & Essences UK business and Rene Laurent business in France that were divested to present fully comparable scenarios. The divestitures were completed on September 1, 2025 and December 1, 2025, respectively.

    (2)

    Scent sales and segment adjusted operating EBITDA information for the year-ended December 31, 2024 exclude the results of the Cosmetic Ingredients business to present fully comparable scenarios. The divestiture was completed on April 1, 2024.

    (3)

    Pharma sales and segment adjusted operating EBITDA information for the three months and year-ended December 31, 2024 exclude the results of the Pharma Solutions disposal group and Nitrocellulose business to present fully comparable scenarios. The divestitures were completed on May 1, 2025 and May 9, 2025, respectively.

    (4)

    Amounts exclude the results of the Cosmetic Ingredients business, the Pharma Solutions disposal group, the Nitrocellulose business, the Flavors & Essences UK business and Rene Laurent France business that were divested in the second quarter of 2024 (April 2, 2024), second quarter of 2025 (May 1, 2025), second quarter of 2025 (May 9, 2025), third quarter of 2025 (September 1, 2025) and fourth quarter of 2025 (December 1, 2025), respectively, to present fully comparable scenarios.

    (5)

    Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Food Ingredients, Health & Biosciences, and Scent segments to align with the updated 2025 operating model.

     

     

    Three Months Ended December 31, 2025

     

     

    Selling & Administrative Expenses

     

    Research & Development Expenses

     

    Total Adjusted Operating EBITDA Impact

    Taste

     

    $

    3

     

    $

    1

     

    $

    (4

    )

    Food Ingredients

     

     

    3

     

     

    —

     

     

    (3

    )

    Health & Biosciences

     

     

    3

     

     

    —

     

     

    (3

    )

    Scent

     

     

    2

     

     

    —

     

     

    (2

    )

    Total

     

    $

    11

     

    $

    1

     

    $

    (12

    )

     

     

    Year Ended December 31, 2025

     

     

    Selling & Administrative Expenses

     

    Research & Development Expenses

     

    Total Adjusted Operating EBITDA Impact

    Taste

     

    $

    7

     

    $

    1

     

    $

    (8

    )

    Food Ingredients

     

     

    9

     

     

    —

     

     

    (9

    )

    Health & Biosciences

     

     

    7

     

     

    1

     

     

    (8

    )

    Scent

     

     

    5

     

     

    1

     

     

    (6

    )

    Total

     

    $

    28

     

    $

    3

     

    $

    (31

    )

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    Comparable Foreign Exchange Impact

    (Unaudited)

     

    Q4 Taste

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    2%

     

    8%

     

    1%

    Portfolio Impact

     

    1%

     

    7%

     

    1%

    % Change - Comparable

     

    3%

     

    15%

     

    2%

    Currency Impact

     

    (1)%

     

    2%

     

    0%

    % Change - Comparable Currency Neutral

     

    2%

     

    17%

     

    2%

     

     

     

     

     

     

     

    Q4 Food Ingredients

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    (2)%

     

    (18)%

     

    (2)%

    Portfolio Impact

     

    0%

     

    3%

     

    0%

    % Change - Comparable

     

    (2)%

     

    (15)%

     

    (2)%

    Currency Impact

     

    (2)%

     

    4%

     

    1%

    % Change - Comparable Currency Neutral

     

    (4)%

     

    (11)%

     

    (1)%

     

     

     

     

     

     

     

    Q4 Health & Biosciences

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    7%

     

    14%

     

    2%

    Portfolio Impact

     

    0%

     

    3%

     

    1%

    % Change - Comparable

     

    7%

     

    17%

     

    2%

    Currency Impact

     

    (2)%

     

    3%

     

    1%

    % Change - Comparable Currency Neutral

     

    5%

     

    20%

     

    3%

     

     

     

     

     

     

     

    Q4 Scent

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    6%

     

    0%

     

    (1)%

    Portfolio Impact

     

    0%

     

    1%

     

    0%

    % Change - Comparable

     

    6%

     

    1%

     

    (1)%

    Currency Impact

     

    (2)%

     

    0%

     

    0%

    % Change - Comparable Currency Neutral

     

    4%

     

    1%

     

    (1)%

     

     

     

     

     

     

     

    Q4 Consolidated

     

    Sales

     

    Adjusted Operating EBITDA

     

    Adjusted Operating EBITDA Margin

    % Change - Reported

     

    (7)%

     

    (7)%

     

    0%

    Portfolio Impact

     

    9%

     

    12%

     

    1%

    % Change - Comparable

     

    3%

     

    5%

     

    0%

    Currency Impact

     

    (2)%

     

    2%

     

    1%

    % Change - Comparable Currency Neutral

     

    1%

     

    7%

     

    1%

    ______________________

    Note: The sum of these items may not foot due to rounding.

    International Flavors & Fragrances Inc.

    GAAP to Non-GAAP Reconciliation

    Comparable Foreign Exchange Impact

    (Unaudited)

     

    YTD Taste

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    2%

     

    4%

     

    0%

    Portfolio Impact

     

    1%

     

    3%

     

    0%

    % Change - Comparable

     

    3%

     

    7%

     

    1%

    Currency Impact

     

    1%

     

    3%

     

    0%

    % Change - Comparable Currency Neutral

     

    4%

     

    10%

     

    1%

     

     

     

     

     

     

     

    YTD Food Ingredients

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    (3)%

     

    4%

     

    1%

    Portfolio Impact

     

    0%

     

    2%

     

    0%

    % Change - Comparable

     

    (3)%

     

    6%

     

    1%

    Currency Impact

     

    0%

     

    4%

     

    0%

    % Change - Comparable Currency Neutral

     

    (3)%

     

    10%

     

    2%

     

     

     

     

     

     

     

    YTD Health & Biosciences

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    4%

     

    3%

     

    0%

    Portfolio Impact

     

    0%

     

    2%

     

    0%

    % Change - Comparable

     

    4%

     

    5%

     

    0%

    Currency Impact

     

    (1)%

     

    2%

     

    1%

    % Change - Comparable Currency Neutral

     

    3%

     

    7%

     

    1%

     

     

     

     

     

     

     

    YTD Scent

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    2%

     

    (6)%

     

    (2)%

    Portfolio Impact

     

    1%

     

    3%

     

    1%

    % Change - Comparable

     

    3%

     

    (2)%

     

    (1)%

    Currency Impact

     

    0%

     

    4%

     

    1%

    % Change - Comparable Currency Neutral

     

    3%

     

    2%

     

    0%

     

     

     

     

     

     

     

    YTD Pharma Solutions

     

    Sales

     

    Segment Adjusted Operating EBITDA

     

    Segment Adjusted Operating EBITDA Margin

    % Change - Reported

     

    (65)%

     

    (65)%

     

    0%

    Portfolio Impact

     

    74%

     

    76%

     

    0%

    % Change - Comparable

     

    9%

     

    12%

     

    0%

    Currency Impact

     

    3%

     

    4%

     

    0%

    % Change - Comparable Currency Neutral

     

    12%

     

    16%

     

    1%

     

     

     

     

     

     

     

    YTD Consolidated

     

    Sales

     

    Adjusted Operating EBITDA

     

    Adjusted Operating EBITDA Margin

    % Change - Reported

     

    (5)%

     

    (5)%

     

    0%

    Portfolio Impact

     

    7%

     

    9%

     

    1%

    % Change - Comparable

     

    2%

     

    4%

     

    1%

    Currency Impact

     

    0%

     

    3%

     

    1%

    % Change - Comparable Currency Neutral

     

    2%

     

    7%

     

    1%

    _______________________

    Note: The sum of these items may not foot due to rounding.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260211509419/en/

    Media Relations:

    Paulina Heinkel

    332.877.5339

    Media.request@iff.com

    Investor Relations:

    Michael Bender

    212.708.7263

    Investor.Relations@iff.com

    Get the next $IFF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IFF

    DatePrice TargetRatingAnalyst
    9/8/2025Underperform → Peer Perform
    Wolfe Research
    8/7/2025Outperform → Perform
    Oppenheimer
    6/4/2025$105.00Buy
    Tigress Financial
    5/8/2025$84.00Equal Weight → Overweight
    Barclays
    2/20/2025$77.00Buy → Sell
    CFRA
    1/7/2025Hold → Buy
    Argus
    11/12/2024$111.00 → $110.00Equal-Weight → Overweight
    Morgan Stanley
    11/8/2024$107.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $IFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IFF Reports Fourth Quarter and Full Year 2025 Results

    Delivered solid top and bottom-line performance & advanced strategic priorities in 2025 Launched sale process for the Food Ingredients segment Continuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Reported   Adjusted (GAAP) (Non-GAAP)1 Sales   Loss Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $10.9 B   $(412) M   $(1.46)   $2.1 B

    2/11/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 2026

    IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company's management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay

    1/21/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    $IFF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Landsman Stephen N bought $196,788 worth of shares (3,100 units at $63.48), increasing direct ownership by 26% to 15,100 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    12/12/25 4:18:29 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director Fribourg Paul J bought $1,001,183 worth of shares (15,450 units at $64.80) (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/8/25 6:49:19 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $993,714 worth of shares (15,300 units at $64.95), increasing direct ownership by 25% to 77,370 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/7/25 6:59:38 PM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intl Flavors upgraded by Wolfe Research

    Wolfe Research upgraded Intl Flavors from Underperform to Peer Perform

    9/8/25 8:37:37 AM ET
    $IFF
    Major Chemicals
    Industrials

    Intl Flavors downgraded by Oppenheimer

    Oppenheimer downgraded Intl Flavors from Outperform to Perform

    8/7/25 7:47:58 AM ET
    $IFF
    Major Chemicals
    Industrials

    Tigress Financial initiated coverage on Intl Flavors with a new price target

    Tigress Financial initiated coverage of Intl Flavors with a rating of Buy and set a new price target of $105.00

    6/4/25 10:19:21 AM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Food Ingredients Muller Andres Roberto converted options into 1,825 shares and covered exercise/tax liability with 633 shares (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    1/5/26 5:33:29 PM ET
    $IFF
    Major Chemicals
    Industrials

    EVP, General Counsel Landsman Stephen N bought $196,788 worth of shares (3,100 units at $63.48), increasing direct ownership by 26% to 15,100 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    12/12/25 4:18:29 PM ET
    $IFF
    Major Chemicals
    Industrials

    EVP, Global Operations Officer Finzel Ralf converted options into 10,774 shares and covered exercise/tax liability with 5,214 shares, increasing direct ownership by 60% to 14,859 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    12/2/25 4:20:36 PM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    SEC Filings

    View All

    International Flavors & Fragrances Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    2/11/26 4:24:36 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by International Flavors & Fragrances Inc.

    10-Q - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    11/4/25 4:36:27 PM ET
    $IFF
    Major Chemicals
    Industrials

    International Flavors & Fragrances Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    11/4/25 4:21:11 PM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    Financials

    Live finance-specific insights

    View All

    IFF Reports Fourth Quarter and Full Year 2025 Results

    Delivered solid top and bottom-line performance & advanced strategic priorities in 2025 Launched sale process for the Food Ingredients segment Continuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Reported   Adjusted (GAAP) (Non-GAAP)1 Sales   Loss Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $10.9 B   $(412) M   $(1.46)   $2.1 B

    2/11/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 2026

    IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company's management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay

    1/21/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF Declares Dividend for Fourth Quarter 2025

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 9, 2026 to shareholders of record as of December 19, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All R

    10/30/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    3/8/24 4:44:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    2/13/24 5:07:58 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by International Flavors & Fragrances Inc.

    SC 13G - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    2/13/24 2:02:27 PM ET
    $IFF
    Major Chemicals
    Industrials

    $IFF
    Leadership Updates

    Live Leadership Updates

    View All

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/Brett Icahn (Photo: IFF) These appointments follow the company's previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Her

    10/22/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials